Vinaixa C, Berenguer M

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 322-323
Archivo PDF: 101.38 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149: 649- 659. doi:10.1053/j.gastro.2015.05.010.

2. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685-97. doi:10.1016/S1473-309900052-9.

3. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr., Saab S, Shiffman ML, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-62. doi:10.1002/hep.25976.

4. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr., Fenkel JM, Gordon F, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology 2015; 148. doi:10.1053/ j.gastro.2014.09.023.

5. Donato MF, Morelli C, Romagnoli R, Invernizzi F, Mazzarelli C, Iemmolo RM, Montalbano M, et al. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: A real-life strategy. Liver Int 2016. doi:10.1111/liv.13322.

6. Carrillo CF, Crespo G, de la Revilla J, Castells L, Buti M, Montero JL, Fábrega E, et al. Successful continuation of HCV treatment following liver transplantation. Transplantation 2016: 1. doi:10.1097/TP.0000000000001596.

7. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65(3): 524-31.